Last reviewed 2026-04-22 · How we verify

DWP450

DWP450 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.

DWP450 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

DWP450 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. The drug also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. Its extended half-life allows for less frequent dosing compared to shorter-acting GLP-1 agonists.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Hypoglycemia

Key clinical trials

• DWP450 for Treating Moderate to Severe Glabellar Lines (PHASE3)
• Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy (PHASE3)
• Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006 (PHASE2)
• Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines (PHASE2)
• A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002 (PHASE3)
• A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001 (PHASE3)
• Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity (PHASE4)
• DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.